Skip to main content
. 2015 Nov 2;6(36):38458–38468. doi: 10.18632/oncotarget.6276

Figure 1.

Figure 1

A. Western Blot analyses of HCC827, PC9, H1975 and HCC827GR cells treated with 0.1μM, 1μM or 10μM of erlotinib or DMSO for 20 minutes or continuously till preparation of lysates. Whole-cell lysates were analyzed for expression levels of the indicated proteins by western blotting. B. AnnexinV flow cytometry of HCC827, PC9, H1975 and HCC827GR treated with 0.1μM, 1μM, 10μMerlotinib or DMSO for 20 minutes or continuously. FACS-analysis was done 24 hours after initial exposure to erlotinib and read-out was normalized to DMSO-control. Change of Annexin V/PI-double positive cells ±SD are shown. *p < 0.05, **p < 0.001. C. shows relative tumor volumes of xenografts ±SD (HCC827, PC9 and H1975). Xenograft harboring mice were treated with 30mg/kg erlotinib daily or 200mg/kg erlotinib every 2nd day p.o. and tumor volumes were measured every 2nd day.*p < 0.05, **p < 0.001.